JPGN Journal Club November 2024: Rapid Infliximab Monitoring and Lipid Profiling for Pediatric Obesity Risk

November:  Knocking on the door, or already inside and making itself at home ?  Whatever. It’s JPGN Journal Club, led by Dr Jake Mann! Don’t forget ESPGHAN’s other educational offerings:  https://www.espghan.org/knowledge-center – in particular on XI.11 the Winter School on Basic Science and Translational Research; on XI.15 a Masterclass on Transition from Paediatric to Adult Healthcare in Patients with GI or Liver Disease; and on XI.21 the 9th IBD Masterclass.   Jake’s choices for discussion today: From J Pediatr Gastroenterol Nutr, by Bouhuys et al., “Lateral flow test versus enzyme-linked immunosorbent assay to measure infliximab trough concentrations:  A head-to-head comparison” and from Nat Med, by Huang et al., “Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity”.  We learn from the JPGN article that lateral-flow testing results closely match those of the present standard of measurement – and are much more quickly obtained, perhaps permitting earlier intervention in an inflammatory-disease flare.  From the Nat Medarticle we learn that in obese children the lipidome is enriched in species associated with increased disease risk, an enrichment that can be reversed with non-pharmacologic intervention.  Such profiling may be useful in identifying risk and in tracking the efficacy of therapy.     Literature Bouhuys M et al.  Lateral flow test versus enzyme-linked immunosorbent assay to measure infliximab trough concentrations :  A head-to-head comparison.  J Pediatr Gastroenterol Nutr 2024 Oct 10.  DOI :  10.1002/jpn3.12372.  PMID :  39390697   Huang Y et al.  Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity.  Nat Med 2024 Sep 20.  DOI : 10.1038/s41591-024-03279-x.  PMID : 39304782